Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00375427
First received: September 12, 2006
Last updated: April 9, 2012
Last verified: July 2011
Results First Received: February 28, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Breast Cancer With Bone Metastasis
Intervention: Drug: Zoledronic acid

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Total enrollment was 430; five participants were screened but not treated.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Zoledronic Acid Every 3 Months Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized participants received a maximum of 4 infusions in this group.
Zoledronic Acid Every 4 Weeks Zoledronic acid given as a 15-minute (at least) i.v. infusion every 4 weeks. The dose of study drug was the as same administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Participants randomized to this group received up to 12 infusions.

Participant Flow:   Overall Study
    Zoledronic Acid Every 3 Months     Zoledronic Acid Every 4 Weeks  
STARTED     209 [1]   216  
COMPLETED     149     142  
NOT COMPLETED     60     74  
Adverse Event                 21                 27  
Abnormal test procedure result(s)                 0                 1  
Abnormal laboratory value(s)                 1                 2  
Unsatisfactory therapeutic effect                 4                 4  
Patient no longer requires study drug                 3                 7  
Protocol Violation                 10                 8  
Withdrawal by Subject                 9                 13  
Lost to Follow-up                 1                 1  
Administrative reasons                 0                 1  
Death                 11                 10  
[1] Total enrollment was 430 but five patients were screened but not treated.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Zoledronic Acid Every 3 Months Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized participants received a maximum of 4 infusions in this group.
Zoledronic Acid Every 4 Weeks Zoledronic acid given as a 15-minute (at least) i.v. infusion every 4 weeks. The dose of study drug was the as same administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Participants randomized to this group received up to 12 infusions.
Total Total of all reporting groups

Baseline Measures
    Zoledronic Acid Every 3 Months     Zoledronic Acid Every 4 Weeks     Total  
Number of Participants  
[units: participants]
  209     216     425  
Age  
[units: years]
Mean ± Standard Deviation
  60.4  ± 11.9     59.8  ± 11.8     60.1  ± 11.9  
Gender  
[units: participants]
     
Female     209     216     425  
Male     0     0     0  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Annual Overall Skeletal Morbidity Rate (SMR)   [ Time Frame: 12 months ]

2.  Secondary:   Percentage of Participants Experiencing Skeletal Related Event(s) (SREs)   [ Time Frame: 12 month ]

3.  Secondary:   Annual Incidence of Any Skeletal Related Events (SREs)   [ Time Frame: 12 months ]

4.  Secondary:   Median Time to First Skeletal Related Event(s) (SRE)   [ Time Frame: 12 month ]

5.  Secondary:   Percentage of Participants Skeletal Related Event (SRE) Free   [ Time Frame: 12 months ]

6.  Secondary:   Composite Bone Pain Score According to the Brief Pain Inventory (BPI) Questionnaire   [ Time Frame: At Baseline, Month 3, Month 6, Month 9 and Month 12 ]

7.  Secondary:   Evaluation of Pain According to Verbal Rating Scale (VRS) Based on Median Score Value   [ Time Frame: At Baseline, Month 3, Month 6, Month 9 and Month 12 ]

8.  Secondary:   Use Of Analgesic Medications According to the Analgesic Score Scale   [ Time Frame: At Baseline, Month 3, Month 6, Month 9 and Month 12 ]

9.  Secondary:   Assessment of the Eastern Cooperative Oncology Group (ECOG) Performance Score   [ Time Frame: At Baseline, Month 3, Month 6, Month 9 and Month 12 ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Study Director
Organization: Novartis Pharmaceuticals
phone: 862-778-8300


No publications provided


Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT00375427     History of Changes
Other Study ID Numbers: CZOL446EIT14
Study First Received: September 12, 2006
Results First Received: February 28, 2011
Last Updated: April 9, 2012
Health Authority: Italy: Ethics Committee